Ceftobiprole no tratamento de pacientes com infecções bacterianas agudas da pele e da estrutura da pele
Um estudo randomizado, duplo-cego e multicêntrico para estabelecer a segurança e a eficácia do ceftobiprole medocaril em comparação com vancomicina mais aztreonam no tratamento de infecções bacterianas agudas da pele e da estrutura da pele
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients with ABSSSIs. Randomization was stratified by study site and type of ABSSSI (with major cutaneous abscess comprising ≤ 30% of the Intent-to-Treat [ITT] population).
Primary endpoint for FDA: Early clinical response based on the percent reduction in lesion size at 48-72 hours compared to baseline in patients who did not receive rescue therapy and were alive, in the ITT population.
Primary endpoint for EMA: Investigator-assessed clinical success at the test-of-cure (TOC) visit 15-22 days after randomization, in the co-primary ITT and Clinically Evaluable (CE) populations.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Pleven, Bulgária, 5800
- University Multiprofile Hospital for Active Treatment
-
Plovdiv, Bulgária, 4004
- University Multiprofile Hospital for Active Treatment
-
Rousse, Bulgária, 7002
- University Multiprofile Hospital for Active Treatment
-
Sofia, Bulgária, 1606
- "University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N. I. Pirogov"", Clinic of Purulent-Septic Surgery-"N.I. Pirogov""
-
-
-
-
California
-
Anaheim, California, Estados Unidos, 92804
- Saint Joseph's Clinical Research
-
Anaheim, California, Estados Unidos, 92804
- Physician Alliance Research Center
-
Chula Vista, California, Estados Unidos, 91911
- eStudySite - Chula Vista - PPDS
-
Fresno, California, Estados Unidos, 93721
- Central Valley Research LLC
-
Huntington Beach, California, Estados Unidos, 92647
- Marvel Clinical Research
-
La Mesa, California, Estados Unidos, 91942
- eStudySite - La Mesa - PPDS
-
La Palma, California, Estados Unidos, 90623
- Omnibus Clinical Research
-
Long Beach, California, Estados Unidos, 90813
- Alliance Research LLC
-
Long Beach, California, Estados Unidos, 90813
- Long Beach Clinical Trials
-
Modesto, California, Estados Unidos, 95350
- Central Valley Research, LLC
-
-
Florida
-
Coral Gables, Florida, Estados Unidos, 33134
- Gonzalez MD and Aswad MD Health Services
-
Miami, Florida, Estados Unidos, 33144
- L&C Professional Medical Research Institute
-
-
Montana
-
Butte, Montana, Estados Unidos, 59701
- Mercury Street Medical Group
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89109
- Excel Clinical Research
-
Las Vegas, Nevada, Estados Unidos, 89109
- eStudySite - Las Vegas - PPDS
-
-
New Jersey
-
Somers Point, New Jersey, Estados Unidos, 08244
- South Jersey Infectious Disease
-
-
-
-
-
Kaposvár, Hungria, 7400
- Kaposi Mor Teaching Hospital
-
Miskolc, Hungria, 3529
- CRU Hungary Ltd.
-
Szeged, Hungria, 6720
- University of SzegednAlbert Szent-Gyorgyi Clinical Center
-
Veszprém, Hungria, 8200
- Csolnoky Ferenc Hospital
-
-
-
-
-
Dnipro, Ucrânia, 49005
- Dnipropetrovsk I.I. Mechnуkov Regional Clinical Hospital, Surgery Department #2
-
Ivano-Frankivsk, Ucrânia, 76008
- Ivano-Frankivsk City Clinical Hospital Surgery 1
-
Ivano-Frankivsk, Ucrânia, 76018
- Ivano-Frankivsk City Clinical Hospital General Surgery
-
Kyiv, Ucrânia, 03110
- Kyiv City Clinical Hospital
-
Lviv, Ucrânia, 79000
- Public City Clinical Hospital of Emergency Medical Care
-
Lviv, Ucrânia, 79059
- Lviv Regional Clinical Hospital
-
Uzhhorod, Ucrânia, 88000
- Central City Clinical Hospital
-
Vinnytsia, Ucrânia, 21018
- Vinnytsia M.I. Pyrohov Regional Clinical Hospital
-
Zaporizhia, Ucrânia, 69000
- Zaporizhia City Clinical Hospital of Urgent and Emergency Medical Care
-
Zhytomyr, Ucrânia, 12430
- Central District Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
INCLUSION CRITERIA
-
Male or female, aged ≥18 years.
-
Diagnosis of ABSSSI, meeting at least one of the definitions in (a) to (c) below. Local symptoms must have started within the 7 days prior to the Screening visit:
-
Cellulitis/erysipelas, defined as a diffuse skin infection characterized by all of the following within 24 hours:
-
i. Rapidly spreading areas of erythema, edema, and/or induration with a minimum total lesion surface area of 75cm^2
-
ii. No collection of pus apparent upon visual examination
-
iii. At least two of the following local signs of infection:
- erythema
- induration
- localized warmth
- pain or tenderness on palpation
- swelling/edema
-
-
Major cutaneous abscess, defined as infection characterized by a collection of pus within the dermis or deeper that is apparent upon visual examination before or after therapeutic intervention and is accompanied by all of the following within 24 hours:
-
i. Erythema, edema and/or induration with a minimum total lesion surface area of 75 cm^2.
-
ii. At least two of the following local signs of infection:
- fluctuance
- incision and drainage required
- purulent or seropurulent drainage
- localized warmth
- pain or tenderness on palpation
-
-
Wound infection, defined as infection of any apparent break in the skin characterized by at least one of the following:
-
i. Superficial incision/surgical site infection meeting all of the following criteria:
- involves only the skin or subcutaneous tissue around the incision (does not involve fascia).
- occurs within 30 days of procedure.
- purulent drainage (spontaneous or therapeutic) with surrounding erythema, edema and/ or induration with a minimum total lesion surface area of 75cm^2.
-
ii. Post-traumatic wound (including penetrating trauma, e.g., needle, nail, knife, insect and spider bites) meeting the following criterion within 24 hours:
- Purulent drainage (spontaneous or therapeutic) with surrounding erythema, edema and/or induration with a minimum total lesion surface area of 75cm^2.
-
-
-
At least one of the following regional or systemic signs of infection at the Screening visit:
- Lymph node tenderness and volume increase, or palpable lymph node proximal to the primary ABSSSI.
- Fever > 38 °C/100.4 °F measured orally, > 38.5 °C / 101.3 °F measured tympanically, > 37.5 °C / 99.5 °F measured by the axillary method, or > 39 °C / 102.2 °F measured rectally.
- White blood cell (WBC) count > 10.0 × 10^9/L or < 4.0 × 10^9/L.
- > 10% immature neutrophils (band forms).
-
Requirement for IV antibacterial treatment.
-
Willing and able to adhere to study procedures (including prohibitions and restrictions) as specified in this protocol.
-
Willing and able to remain hospitalized (in a hospital or equivalent medical confinement or clinical research unit) until completion of the early-clinical-response assessment for the primary endpoint.
-
Informed consent signed by the patient, or their legally acceptable representative if appropriate, indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate.
EXCLUSION CRITERIA
Patients meeting any one of the following:
-
Use of any systemic antibacterial treatment within 14 days, or topical antibacterial administration on the primary lesion within 96 hours, before first infusion of study drug.
Exception: Receipt of a single dose of a short acting (half-life ≤ 12 hours) antibacterial therapy (e.g., for surgical prophylaxis) within > 3 days before randomization (i.e., patients cannot have received any antibacterial treatment within 72 hours of randomization).
-
Contraindication to the administration of either of the study treatments, including known clinically-relevant hypersensitivity to related antibacterial treatments (e.g., beta-lactam and glycopeptide antibiotics), or to metronidazole if required as adjunctive therapy.
-
Participation in any other clinical study within the 30 days prior to randomization, or any prior participation in this study.
-
The primary ABSSSI is an uncomplicated skin and skin structure infection, such as furuncles, minor abscesses (area of suppuration not surrounded by cellulitis/erysipelas), impetiginous lesions, superficial or limited cellulitis/erysipelas, or minor wound infections (e.g., stitch abscesses).
-
The primary ABSSSI is due to, or associated with, any of the following:
- Diabetic foot infection, gangrene, or perianal abscess.
- Concomitant infection at another site (e.g., septic arthritis, endocarditis, osteomyelitis), not including a secondary ABSSSI lesion.
- Infected burns.
- Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous).
- Any evolving necrotizing process (e.g., necrotizing fasciitis).
- Infections at vascular catheter sites, or involving thrombophlebitis.
-
The primary ABSSSI is associated with, or in close proximity to, a prosthetic device.
-
Patients who are placed in a hyperbaric chamber as adjunctive therapy for the ABSSSI.
-
Patients expected to require more than two surgical interventions in the operating room for the ABSSSI.
-
Severe sepsis or septic shock.
-
Significant or life-threatening condition (e.g., endocarditis, meningitis) that would confound, or interfere with, the assessment of the ABSSSI.
-
Another severe, acute or chronic medical condition, psychiatric condition, or laboratory abnormality that may increase the risks associated with study participation or administration of the investigational product, or may interfere with the interpretation of study results, and which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
-
Receiving treatment for active tuberculosis.
-
Absolute neutrophil count < 0.5 × 10^9/L.
-
Recent history of opportunistic infections (i.e., within 30 days) if the underlying cause of these infections is still active (e.g., leukemia, transplant, acquired immunodeficiency syndrome [AIDS]).
-
Patients receiving systemic steroids (> 40 mg per day prednisolone, or equivalent), or receiving immunosuppressant drugs.
-
Requirement for peritoneal dialysis, plasmapheresis, hemodialysis, venovenous dialysis, or other forms of renal filtration, or expected to require such treatment before the TOC visit.
-
Alanine transaminase (ALT) or aspartate transaminase (AST) levels ≥ 8× the upper limit of normal, OR severe hepatic disease with Child-Pugh class C.
-
Women who are pregnant or nursing.
-
Women who are of childbearing potential and unwilling to use an acceptable method of birth control during the study: female sterilization (bilateral tubal occlusion or oophorectomy, or hysterectomy) or male partner vasectomy; intrauterine device (IUD); combined (estrogen and progesterone containing) hormonal contraception (oral, vaginal ring, or transdermal patch) with an ethinylestradiol dose of at least 30 µg, plus use of male condoms (preferably with spermicides), female condoms, a female diaphragm or a cervical cap; or total sexual abstinence.
Women are not considered to be of childbearing potential if they are either ≥ 1 year post-menopausal (where menopause is defined as at least 12 months of amenorrhea), or have a serum follicle stimulating hormone (FSH) measurement consistent with post-menopausal status according to local laboratory thresholds. An FSH measurement at Screening is to be obtained for post-menopausal females aged < 50 years, or for those aged ≥ 50 years who have been post-menopausal for < 2 years.
-
Inability to start study-drug therapy within 24 hours of Screening.
-
Patients with illicit drug use within 12 months of screening, including heroin, other opioids (unless prescribed for medical reasons unrelated to heroin substitution), cocaine / crack cocaine, and amphetamine or methamphetamine. Exception: Cannabis use.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: ceftobiprole medocaril
Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment). |
ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
Outros nomes:
|
|
Comparador Ativo: vancomycin+aztreonam
Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment). |
Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor. Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was < 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Early Clinical Response
Prazo: 48-72 hours after start of study drug treatment
|
Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population |
48-72 hours after start of study drug treatment
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Investigator-assessed Clinical Success in the ITT Population
Prazo: 15-22 days after randomization
|
Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT population |
15-22 days after randomization
|
|
Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population
Prazo: 15-22 days after randomization
|
Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population |
15-22 days after randomization
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Diretor de estudo: Marc Engelhardt, MD, Basilea Pharmaceutica
Publicações e links úteis
Publicações Gerais
- Welte T, Scheeren TW, Overcash JS, Saulay M, Engelhardt M, Hamed K. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. Future Microbiol. 2021 May;16:543-555. doi: 10.2217/fmb-2021-0042. Epub 2021 May 7.
- Overcash JS, Kim C, Keech R, Gumenchuk I, Ninov B, Gonzalez-Rojas Y, Waters M, Simeonov S, Engelhardt M, Saulay M, Ionescu D, Smart JI, Jones ME, Hamed KA. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Clin Infect Dis. 2021 Oct 5;73(7):e1507-e1517. doi: 10.1093/cid/ciaa974.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- BPR-CS-008
- HHSO100201600002C (Número de outro subsídio/financiamento: BARDA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .